$46.62
2.65% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Janux Therapeutics Inc Stock price

$46.62
+0.23 0.50% 1M
+7.78 20.03% 6M
+35.89 334.48% YTD
+36.68 369.01% 1Y
+21.82 87.98% 3Y
+21.47 85.37% 5Y
+21.47 85.37% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
-1.27 2.65%
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Key metrics

Market capitalization $2.43b
Enterprise Value $1.81b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 119.59
P/S ratio (TTM) P/S ratio 160.73
P/B ratio (TTM) P/B ratio 3.70
Revenue growth (TTM) Revenue growth 94.86%
Revenue (TTM) Revenue $15.13m
EBIT (operating result TTM) EBIT $-65.93m
Free Cash Flow (TTM) Free Cash Flow $-47.75m
Cash position $646.29m
EPS (TTM) EPS $-0.92
P/E forward negative
P/S forward 215.64
EV/Sales forward 161.91
Short interest 12.56%
Show more

Is Janux Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.

Janux Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Janux Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Janux Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Janux Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
15 15
95% 95%
100%
- Direct Costs 2.07 2.07
31% 31%
14%
13 13
111% 111%
86%
- Selling and Administrative Expenses 24 24
8% 8%
157%
- Research and Development Expense 53 53
11% 11%
351%
-64 -64
16% 16%
-422%
- Depreciation and Amortization 2.07 2.07
31% 31%
14%
EBIT (Operating Income) EBIT -66 -66
15% 15%
-436%
Net Profit -44 -44
35% 35%
-291%

In millions USD.

Don't miss a Thing! We will send you all news about Janux Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Janux Therapeutics Inc Stock News

Neutral
Business Wire
about 2 months ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights.
Neutral
Business Wire
2 months ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to ...
Positive
Seeking Alpha
3 months ago
Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer drug candidates that activate T cells in the tumor microenvironment, showing promising results in clinical trials. JANX007 achieved a 50% PSA reduction in 83% of mCRPC patients at 0.2mg or higher. ...
More Janux Therapeutics Inc News

Company Profile

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO David Campbell
Employees 64
Founded 2017
Website www.januxrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today